Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471662 | 0.84 | CYP3A4 (0.43) | POLBALDH1A1CYP3A4SMN1; SMN2ROCK2 | |
| SCHEMBL2476635 | 0.83 | POLB (0.41) | POLBALDH1A1CYP3A4SMN1; SMN2ROCK2 | |
| SCHEMBL2479016 | 0.81 | POLB (0.54) | POLBALDH1A1SMN1; SMN2CA12CA1 | |
| SCHEMBL2478187 | 0.79 | ALDH1A1 (0.43) | POLBALDH1A1CYP3A4ROCK2 | |
| SCHEMBL2474178 | 0.79 | POLB (0.60) | POLBALDH1A1SMN1; SMN2RECQLCA12 | |
| SCHEMBL2473765 | 0.79 | POLB (0.48) | POLBALDH1A1CYP3A4SMN1; SMN2ROCK2 | |
| SCHEMBL9988581 | 0.79 | POLB (0.50) | POLBALDH1A1CYP3A4SMN1; SMN2CA1 | |
| SCHEMBL2478969 | 0.76 | ALDH1A1 (0.46) | POLBALDH1A1SMN1; SMN2RECQLPIK3R1 | |
| SCHEMBL2472340 | 0.76 | CYP3A4 (0.38) | POLBALDH1A1CYP3A4SMN1; SMN2ROCK2 | |
| SCHEMBL2475847 | 0.72 | POLB (0.51) | POLBALDH1A1SMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373633-B1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | BOREALIS AGROLINZ MELAMINE (AT) | 2014-04-16 | — | — | EP | disclosed |
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-12-01 | — | — | US | disclosed |
| EP-2373633-A1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | Borealis Agrolinz Melamine GmbH (AT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066683-A1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | CA3, CA7, KAT5 | POLB 2669/4885ALDH1A1 1014/4885CYP3A4 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.